Sunday, 19 September, 2021

Contempt rule issued against health secy, DGHS DG

  • Staff Correspondent
  • 12 August, 2021 12:00 AM
  • Print news
Contempt rule issued against health secy, DGHS DG

Popular News

The High Court has issued a rule against Health Secretary Lokman Hossain Mia and Director General of the Directorate General of Health Service (DGHS) Dr Abul Bashar Mohammad Khurshid and three others, asking them to explain why they shall not be punished for contempt of court.

They are facing the rule for disobeying the February 13, 2017 verdict of the HC which asked them to stop production of harmful antibiotic medicine by Indo-Bangla Pharmaceuticals in Barishal without following Good Manufacturing Practice (GMP).

Three other officials facing contempt rule are  Director General of Department of Consumer Protection Bablu Kumar Shah,  Director General of Drug Administration Major General Mahbubur Rahman and managing director of Indo-Bangla Pharmaceuticals Anwarul Haque.

A division bench comprising Justice Mamnoon Rahman and Justice Khandaker Diliruzzaman issued the contempt rule, following a petition filed by the Human Rights and Peace for Bangladesh (HRPB).

The contemnors will have to submit reply to the rule of the High Court within four weeks.

Appearing for the petitioner, Supreme Court lawyer and HRPB president Manzill Murshid said antibiotics are a lifesaving medicine. But Indo-Bangla Pharmaceuticals is producing antibiotics without following GMP and marketing those.

Drug Administration and other authorities are not taking any action against the company ignoring the apex court order and committing punishable offence.

On 13 February, 2017, the High Court passed an order, directing the government to halt production of 20 pharmaceutical companies and production of antibiotics, following a writ petition filed by HRPB.

The companies are Avert Pharma, Bikalpa Pharmaceutical, Dolphin Pharmaceuticals, Drugland, Exim Pharmaceutical, Globe Laboratories, Jalpa Laboratories and Kafina Pharmaceuticals, Medico Pharmaceutical, National Drug, North Bengal Pharmaceutical, Rimo Chemical, Rid Pharmaceutical, Skylab Pharmaceutical, Spark Pharmaceutical, Star Pharmaceutical, Sunipun Pharmaceutical, Today Pharmaceutical, Tropical Pharmaceutical and Universal Pharmaceutical.

Talking to the Daily Sun, Manzill Murshid said, “Indo-Bangla Pharmaceuticals continues to produce the antibiotics although other companies reportedly stopped production. Indo-Bangla Pharmaceuticals is producing the antibiotics without following GMP. If chemicals and ingredients of the medicine are not preserved in the proper temperature and environment, those change their characters and become harmful for human body.”